Entheon will utilize Divergence’s expertise to consult on planning, research, and development of the DMT Biomarker Model and the Application to predict acute responses to DMT based on the analysis of EEG data.
Vancouver, British Columbia--(Newsfile Corp. - January 19, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTC Pink: ENTBF) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced a partnership with Divergence Neuro Technologies Inc. (“Divergence”), a company focused on the research and development of a data-driven, cloud-based neuro platform based on electroencephalogram (“EEG”) analysis and machine learning, to research and develop N, N-Dimethyltryptamine (“DMT”) biomarkers (“Biomarkers”) and a predictive model of biomarker responses to drug dosage and delivery of DMT-based psychedelic therapeutic products (the “DMT Products”) targeted to treat a number of different addiction and substance use disorders (hereto referred to as the “DMT Biomarker Model”). Divergence will also develop a software platform (the “Application”) that supports the tracking of EEG data during pre, intra, and post dosing using, among other prediction models, the DMT Biomarker Model.
Entheon will utilize Divergence’s expertise to consult on planning, research, and development of the DMT Biomarker Model and the Application to predict acute responses to DMT based on the analysis of EEG data. Divergence will lead the process of integrating EEG into Entheon’s DMT-therapy platform with the ultimate goal of incorporating the technology for use by any clinics utilizing DMT products for the treatment of substance use disorders.
The Application to be developed is a predictive analytics platform that can infer neuro-state change, based on EEG data, during the uptake of DMT while utilizing machine-learning and AI technology, leveraging Divergence’s innovative brain mapping technology with the purpose of guiding drug dosage levels and delivery of DMT during the therapy process.
The Application to be built using the DMT Biomarker Model, at its core, will be a platform that generates highly reliable predicative indicators relating to brain state change following the administration of DMT. The Application will rely on the real-time input of high-fidelity brainwaves to be collected from clinical trial participants and patients to provide feedback on the psychedelic-therapy experience.
Beyond DMT, the Application will be used to aggregate and analyze datasets extending to other psychedelics and therapeutic compounds in order to develop profiles and biomarkers that will be used to inform and guide patient experience and outcomes.
“This partnership represents an exciting direction related to the use of EEG and brain-mapping technology that will ultimately be used to better inform and direct the psychedelic-assisted psychotherapy process,” said Chief Executive Officer of Entheon, Timothy Ko. “The proven and accomplished team at Divergence is well-equipped to lead this EEG and biomarker research, and only furthers our mission of using data to better understand the unique patient experience before, during, and after psychedelic-assisted psychotherapy. We hope that this data-informed approach yields insights that physicians can use in more accurately assessing patients and prescribing medicines in a highly personalized way.”
“We are excited to work with a world-leader in the field of psychedelic-assisted psychotherapy like Entheon on a project that has deep implications for the future of mental health,” said Alex Ni, Chief Executive Officer of Divergence. “We are deeply grounded in the belief that applied neuroscience, when combined with cloud, AI, and mobility, will bring enormous positive and meaningful enhancement in the space of mental health care.”
About Entheon Biomedical Corp.
Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N,N-dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.
About Divergence Neuro Technologies Inc.
Divergence is a Toronto-based company focused on the research and development of a data-driven, cloud-based neuro platform based on EEG-analysis and machine learning to improve mental health for all.
Divergence’s platform and research enhance clinical and personal mental health assessments by supplementing self-reporting methods with an easy-to-understand, cloud-based EEG software platform, offering individualized neurofeedback protocols driven by machine learning and AI combined with therapist interaction.
On Behalf of the Board of Directors,
“Timothy Ko”
Timothy Ko, CEO
For more information, please contact the Company at:
Entheon Biomedical Corp.
Joseph Cullen, Investor Relations
Telephone: +1 (778) 919-8615
m/Joe@entheonbiomedical.com
https://entheonbiomedical.com/
For media inquiries, please contact Crystal Quast at:
Bullseye Corporate
Crystal Quast
Telephone: +1 (647) 529-6364
Quast@BullseyeCorporate.com
Cautionary Note on Forward-Looking Information
This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the partnership with Divergence Neuro Technologies Inc., research and development of the Biomarkers, the development of the Application, and other matters. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Company. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to raise further capital and the Company’s ability to obtain regulatory and exchange approvals. Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
Neither the CSE nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72312
